Xencor Inc Form 10-Q November 04, 2015 Table of Contents
AvailableForSaleSecuritiesGrossUnrealizeLoss
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36182

T 7	-
Xencor.	Inc
ACHCOL.	. IIIC.

(Exact Name of Registrant as Specified in its Charter)

Delaware 20-1622502

(State or Other Jurisdiction of Incorporation (I.R.S. Employer Identification No.)

or Organization)

111 West Lemon Avenue, Monrovia, CA 91016 (Address of Principal Executive Offices) (Zip Code)

(626) 305-5900

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes No

Indicate the number of shares of each of the issuer's classes of common stock, as of the latest practicable date:

Class Outstanding at October 28, 2015

Common stock, \$0.01 par value 40,477,003

Table of Contents

Xencor, Inc.

Quarterly Report on FORM 10-Q for the quarter ended September 30, 2015

Table of Contents

		Page
	SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS	3
PART I.	FINANCIAL INFORMATION	4
Item 1.	Financial Statements	4
	Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014	4
	Statements of Comprehensive Loss for the Three Months and Nine Months ended September 30,	
	2015 and 2014 (unaudited)	5
	Statement of Stockholders' Equity as of September 30, 2015 (unaudited)	6
	Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014 (unaudited)	7
	Notes to Financial Statements (unaudited)	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	26
PART II.	OTHER INFORMATION	27
Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51
Item 6.	<u>Exhibits</u>	52
Signatures		53

In this report, unless otherwise stated or the context otherwise indicates, references to "Xencor," "the Company," "we," "us," "our" and similar references refer to Xencor, Inc. The Xencor logo is a registered trademark of Xencor, Inc. This report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.

2

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estin "project", "may", "will", "should", "could", "could", "can", the negatives thereof, variations thereon and similar expressions, discussions of strategy.

All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:

- · our plans to develop and commercialize our product candidates;
- · our ongoing and planned clinical trials;
- the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
- · our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- · our ability to identify additional products or product candidates with significant commercial potential that are consistent with our business objectives;
- · the rate and degree of market acceptance and clinical utility of our products;
- · the capabilities and strategy of our suppliers and vendors including key manufacturers of our clinical drug supplies;
- · significant competition in our industry;

- · costs of litigation and the failure to successfully defend lawsuits and other claims against us;
- · our partners' ability to advance drug candidates into, and successfully complete, clinical trials;
- · our ability to receive research funding and achieve anticipated milestones under our collaborations;
- · our intellectual property position;
- · loss or retirement of key members of management;
- · costs of compliance and our failure to comply with new and existing governmental regulations;
- · failure to successfully execute our growth strategy, including any delays in our planned future growth; and
- · our failure to maintain effective internal controls.

The factors, risks and uncertainties referred to above and others are more fully described under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December, 31, 2014, as amended, as updated from time to time in Current Reports on Form 8-K. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

3

Table of Contents

PART I — FINANCIAL INFORMATION

Item1. Financial Statements

Xencor, Inc.

Balance Sheets

(In thousands, except share amounts)

Assets	September 30, 2015 (unaudited)		December 31, 2014	
Current assets				
Cash and cash equivalents	\$	57,738	\$	54,649
Marketable securities	Ψ	70,206	Ψ	J+,0+7 —
Accounts receivable		408		2,966
Interest receivable		659		
Prepaid expenses and other current assets		865		134
Total current assets		129,876		57,749
Property and equipment		, , , , ,		,
Computers, software and equipment		5,275		4,270
Furniture and fixtures		102		97
Leasehold improvements		3,612		3,086
Less accumulated depreciation and amortization		(6,696)		(6,554)
Property and equipment, net		2,293		899
Other assets				
Patents, licenses, and other intangible assets, net		9,617		9,116
Marketable securities - long term		69,632		
Other assets		63		59
Total other assets		79,312		9,175
Total assets	\$	211,481		